Key findings from case-based scenarios include a strong preference for observation and surveillance in cases of completely resected IDH-mutant grade 2 gliomas, with a notable shift towards standard salvage therapy and consideration of vorasidenib at recurrence. The gene discussed is IDH1; the disease is central nervous system cancer.